303 related articles for article (PubMed ID: 27830705)
1. Theranostic barcoded nanoparticles for personalized cancer medicine.
Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
[TBL] [Abstract][Full Text] [Related]
2. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
3. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
[TBL] [Abstract][Full Text] [Related]
4. Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine.
Moorthy H; Govindaraju T
ACS Appl Bio Mater; 2021 Feb; 4(2):1115-1139. PubMed ID: 35014470
[TBL] [Abstract][Full Text] [Related]
5. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment.
Deng ZJ; Morton SW; Ben-Akiva E; Dreaden EC; Shopsowitz KE; Hammond PT
ACS Nano; 2013 Nov; 7(11):9571-84. PubMed ID: 24144228
[TBL] [Abstract][Full Text] [Related]
6. "Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
Su S; Tian Y; Li Y; Ding Y; Ji T; Wu M; Wu Y; Nie G
ACS Nano; 2015 Feb; 9(2):1367-78. PubMed ID: 25611071
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
[TBL] [Abstract][Full Text] [Related]
8. Special Issue "Recent Advances in Precision Nanomedicine for Cancer".
Brignole C; Pastorino F
Molecules; 2020 Sep; 25(18):. PubMed ID: 32927825
[TBL] [Abstract][Full Text] [Related]
9. Supramolecular cancer nanotheranostics.
Zhou J; Rao L; Yu G; Cook TR; Chen X; Huang F
Chem Soc Rev; 2021 Feb; 50(4):2839-2891. PubMed ID: 33524093
[TBL] [Abstract][Full Text] [Related]
10. Photoacoustic-based nanomedicine for cancer diagnosis and therapy.
Sim C; Kim H; Moon H; Lee H; Chang JH; Kim H
J Control Release; 2015 Apr; 203():118-25. PubMed ID: 25701310
[TBL] [Abstract][Full Text] [Related]
11. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
[TBL] [Abstract][Full Text] [Related]
12. A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.
Shen J; Kim HC; Wolfram J; Mu C; Zhang W; Liu H; Xie Y; Mai J; Zhang H; Li Z; Guevara M; Mao ZW; Shen H
Nano Lett; 2017 May; 17(5):2913-2920. PubMed ID: 28418672
[TBL] [Abstract][Full Text] [Related]
13. A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected].
Wang H; Agarwal P; Zhao S; Yu J; Lu X; He X
Nat Commun; 2015 Dec; 6():10081. PubMed ID: 26621191
[TBL] [Abstract][Full Text] [Related]
14. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
16. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
[TBL] [Abstract][Full Text] [Related]
17. Nanotheranostics for Diagnosis and Treatment of Breast Cancer.
Patel P; Kumar K; Jain VK; Popli H; Yadav AK; Jain K
Curr Pharm Des; 2023; 29(10):732-747. PubMed ID: 36999427
[TBL] [Abstract][Full Text] [Related]
18. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Targeting Multifunctional Rattle-Type Theranostic Nanoparticles for MRI/NIRF Bimodal Imaging and Delivery of Hydrophobic Drugs.
Jiao Y; Sun Y; Tang X; Ren Q; Yang W
Small; 2015 Apr; 11(16):1962-74. PubMed ID: 25504837
[TBL] [Abstract][Full Text] [Related]
20. Smart IR780 Theranostic Nanocarrier for Tumor-Specific Therapy: Hyperthermia-Mediated Bubble-Generating and Folate-Targeted Liposomes.
Guo F; Yu M; Wang J; Tan F; Li N
ACS Appl Mater Interfaces; 2015 Sep; 7(37):20556-67. PubMed ID: 26322900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
